VIRIDIEN 89.600 € (-2,24 %)
CVC CAPITAL 13.570 € (-3,07 %)
EIFFAGE 108.150 € (-0,87 %)
BOUYGUES 43.870 € (-1,15 %)
AYVENS 11.250 € (0,00 %)
CAPITAL B 0.489 € (-2,63 %)
KERING 242.350 € (-1,96 %)
AIR LIQUIDE 172.880 € (-0,17 %)
ABN AMRO BANK N.V. 41.980 € (+0,70 %)
HERMES INTL 1 531.000 € (-0,75 %)
SANOFI 76.980 € (+0,16 %)
CARREFOUR 16.070 € (+0,44 %)
LINEDATA SERVICES 44.300 € (-3,90 %)
MAGNUM 16.964 € (-0,92 %)
ADYEN 1 022.600 € (+1,57 %)
LVMH 437.150 € (-1,76 %)
KPN KON 4.040 € (-1,25 %)
CAPGEMINI 104.750 € (-1,74 %)
DRONE VOLT 0.410 € (+7,33 %)
AHOLD DEL 30.580 € (-0,84 %)
MAUREL ET PROM 8.140 € (+1,18 %)
BNP PARIBAS ACT.A 102.160 € (-0,43 %)
SCHNEIDER ELECTRIC 286.250 € (-0,68 %)
NN GROUP 77.700 € (-0,51 %)
SHELL PLC 40.285 € (+0,32 %)
VEOLIA ENVIRON. 32.080 € (-1,47 %)
IPSEN 165.900 € (-1,07 %)
ARCELORMITTAL SA 62.480 € (-1,98 %)
APERAM 45.560 € (-3,02 %)
BUREAU VERITAS 27.160 € (-0,11 %)
ASML HOLDING 1 428.800 € (-0,46 %)
VINCI 112.650 € (-1,27 %)
IMCD 96.700 € (-1,45 %)
SAFRAN 329.400 € (-0,66 %)
EMEIS 13.140 € (-0,38 %)
ING GROEP N.V. 31.000 € (+1,42 %)
UMG 14.215 € (-0,94 %)
VIVENDI SE 1.567 € (-1,38 %)
SOCIETE GENERALE 71.890 € (-1,91 %)
L'OREAL 383.200 € (+1,01 %)
DANONE 64.080 € (-0,71 %)
AALBERTS NV 42.200 € (-1,59 %)
PROSUS 36.760 € (-1,58 %)
SODEXO 58.550 € (+0,26 %)
AXA 43.340 € (-0,85 %)
STMICROELECTRONICS 42.675 € (+0,87 %)
NICOX 0.386 € (+0,65 %)
STIF 48.700 € (+2,31 %)
ELIOR GROUP 2.052 € (-0,39 %)
UNILEVER 55.620 € (-0,96 %)
SBM OFFSHORE 34.900 € (-2,13 %)
ABIVAX 98.000 € (-0,46 %)
SAINT GOBAIN 74.940 € (-2,01 %)
HEINEKEN 71.760 € (-1,18 %)
TOTALENERGIES 77.720 € (+0,14 %)
AIRBUS 194.740 € (-0,73 %)
CREDIT AGRICOLE 18.445 € (-0,73 %)
BAM GROEP KON 11.470 € (-1,21 %)
ENGIE 24.190 € (-0,86 %)
VOPAK 47.880 € (-0,66 %) |
02/09/2026 09:40
Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to participate in trial for innovative mapping and pulsed field ablation systemEQS-News: Texas Cardiac Arrhythmia Institute at St. David's Medical Center / Key word(s): Miscellaneous AUSTIN, Texas, Sept. 2, 2026 /PRNewswire/ -- The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first facility in the nation to participate in a clinical trial to evaluate the safety and effectiveness of a next-generation mapping and pulsed field ablation system to treat patients with paroxysmal and persistent atrial fibrillation. Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., executive medical director of TCAI and the global principal investigator for the trial, performed the first procedure. Atrial fibrillation, the most common type of arrhythmia, affects millions of people globally. It occurs when the top two chambers of the heart beat too fast and with an irregular rhythm. Paroxysmal atrial fibrillation is an arrhythmia with symptoms that last for seven days or fewer, while persistent atrial fibrillation is a sustained arrhythmia that lasts for more than a week. Early treatment of paroxysmal and persistent atrial fibrillation can reduce the risk of blood clots, stroke and heart failure—and may prevent the disease from becoming permanent. "Pulsed field ablation represents one of the most significant advancements in electrophysiology in decades, and this clinical trial will help physicians around the world better understand the safety and effectiveness of this technology," Dr. Natale said. "The Texas Cardiac Arrhythmia Institute remains at the forefront of arrhythmia care, helping to advance technologies that will shape the future of electrophysiology." The novel catheter system relies on electric fields to ablate targeted heart tissue without using the excess heat or cold used in traditional ablation, helping to reduce the risk of damage to surrounding structures. The system incorporates advanced 3D cardiac mapping technology that provides a detailed view of the heart's electrical activity, enabling physicians to visualize catheter position and tissue contact before and after the energy is delivered. During a traditional ablation procedure, a catheter is guided into the interior of the heart and uses extreme heat or cold to destroy tissue associated with abnormal heart rhythms, creating a greater chance that surrounding structures will be damaged. TCAI is a state-of-the-art Electrophysiology Center that includes six labs equipped with advanced technology where a group of renowned cardiac electrophysiologists perform a high volume of the most complex electrophysiology procedures. ![]() 02.09.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. 2392578 02.09.2026 CET/CEST Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière
